Risky Business: How to de-risk your ATMP asset to attract investment
Cell and gene therapies have emerged as ground-breaking advancements in the field of medicine, offering the potential for revolutionary treatments for a wide range of diseases. However, the journey from development to commercialisation of these therapies is not without its challenges and risks.
In this blog, Neelam Panchal, Senior Commercialisation of Research and Investment Manager at the Cell and Gene Therapy Catapult, shares why it is crucial to thoroughly understand the potential challenges and risks from both a founder and investor perspective to improve the chances of long-term success. This is the first in a series of blogs to help academic leaders identify and focus on key considerations when seeking investment to commercialise their advanced therapy concepts.
Published on the 21st of september 2023. Read the full news post following this link.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2024). Risky Business: How to de-risk your ATMP asset to attract investment. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/11osp





